106105-17-3 Usage
Uses
Used in Pharmaceutical Industry:
((2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy)acetic acid is used as a pharmaceutical agent for its potential therapeutic properties. It has been studied for its anti-inflammatory and analgesic effects, making it a candidate for the development of drugs to treat pain and inflammation.
Used in Diabetes Treatment:
((2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy)acetic acid is being investigated for its potential use in the treatment of diabetes. Its effects on glucose metabolism and insulin sensitivity could contribute to the development of new treatments for diabetes management.
Used in Cardiovascular Disease Treatment:
((2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy)acetic acid is also being explored for its potential application in the treatment of cardiovascular diseases. Its impact on lipid profiles, blood pressure, and other cardiovascular risk factors could lead to the development of new therapies for heart disease and stroke prevention.
Further research is needed to fully understand the biological and pharmacological activities of ((2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-yl)oxy)acetic acid and to determine its potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 106105-17-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,6,1,0 and 5 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 106105-17:
(8*1)+(7*0)+(6*6)+(5*1)+(4*0)+(3*5)+(2*1)+(1*7)=73
73 % 10 = 3
So 106105-17-3 is a valid CAS Registry Number.
InChI:InChI=1/C20H24Cl2O4/c1-2-3-8-20(13-6-4-5-7-13)10-12-9-14(26-11-15(23)24)17(21)18(22)16(12)19(20)25/h9,13H,2-8,10-11H2,1H3,(H,23,24)
106105-17-3Relevant articles and documents
SWELL1-LRRC8 COMPLEX MODULATORS
-
, (2020/12/30)
The present invention is directed to various polycyclic compounds and methods of using these compounds to treat a variety of diseases including metabolic diseases such as obesity, diabetes, nonalcoholic fatty liver disease; cardiovascular diseases such as hypertension and stroke; neurological diseases, male infertility, muscular disorders, and immune disorders.
Treatment of gray matter edema
-
, (2008/06/13)
The invention relates to the treatment of gray matter edema in the brain or spinal cord by the administration of (indanyloxy)acetic acids, and analogs and salts thereof.
Treatment of brain injury due to gray matter edema with (indanyloxy) butanoic acids
-
, (2008/06/13)
The invention relates to the treatment and prevention of injury to the gray matter of the brain and to the spinal chord due to accidents, ischemic stroke, cardiac arrest, arrested breathing, Reye's syndrome and hydrocephalus by the administration of (indanyloxy)butanoic acids, their derivatives, analogs and salts thereof.
Agents for the treatment of brain injury. 1. (Aryloxy)alkanoic acids
Cragoe Jr.,Gould,Woltersdorf Jr.,Ziegler,Bourke,Nelson,Kimelberg,Waldman,Popp,Sedransk
, p. 567 - 579 (2007/10/02)
Blunt and ischemic injuries of the brain have been shown to result in swelling that is predominantly limited to a single cell type, the astrocyte, within the complex cellular mosaic of cerebral gray matter. Evaluation of various diuretic (aryloxy)acetic a
